Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT.

@article{Denardo2003EnhancedTI,
  title={Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT.},
  author={Sally J. Denardo and Gerald L. Denardo and Aina Yuan and Carol M. Richman and Robert T O'donnell and Primo N. Lara and David L. Kukis and Arutselvan Natarajan and Kathleen R. Lamborn and Frederik J Jacobs and Christine L. Hartmann Siantar},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2003},
  volume={9 10 Pt 2},
  pages={3938S-44S}
}
PURPOSE Radioimmunotherapy delivered by radiometal immunoconjugates and followed by marrow support is dose limited by deposition of radioactivity in normal organs. To increase elimination of radioactivity from the liver and body and, thus, minimize hepatic radiation dose, a peptide having a specific cathepsin B cleavage site was placed between the… CONTINUE READING